Cleveland Clinic Foundation
Cleveland, Ohio, 44195, United States
NCT Number: NCT05608915
Postural instability, freezing-of-gait (FOG), and falls are among the greatest unmet needs in Parkinson disease (PD). FOG eventually affects more than half of people with PD, and is notoriously difficult to treat pharmacologically or via deep brain stimulation. Visual cues do improve gait freezing, but their efficacy and adoption is limited because they are not practical to use in all real-world situations. There is a need for a cueing technique that is on-demand and discreet - only perceptible to the patient. Fortunately, recent technological advances in augmented-reality (AR) enable such an approach. In this study, state-of-the-art AR glasses will be used to project digital cues that are only visible to the wearer, to determine if they can improve FOG. 36 individuals with PD and FOG will be recruited to perform an obstacle-course gait task under six cue conditions: no cue, conventional cue, constant-on AR, patient-hand-triggered AR (turns on when patient clicks button), patient-eye-triggered AR (turns on when looking down), and examiner-triggered AR. The AR cue is a set of images that appear on the floor at a patient's feet, mimicking floor lines. Gait performance will be captured on video and via body-worn wireless sensors that detect how each limb is moving. The investigators will determine whether individuals are cue-able with conventional visual cues, whether intermittent cues outperform constant-on cues, and whether cues triggered by an examiner outperform cues triggered by patients themselves.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Not applicable
Cleveland, Ohio, 44195, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
There will be no visual cues at all. Will be tested off-medication (after holding morning dopaminergic medications).
Physical lines taped to floor at regular intervals. Will be tested off-medication (after holding morning dopaminergic medications).
The augmented-reality visual cue will always be turned on. Will be tested off-medication (after holding morning dopaminergic medications).
The augmented-reality visual cue will be turned on, intermittently, each time the patient clicks a handheld button. Will be tested off-medication (after holding morning dopaminergic medications).
The augmented-reality visual cue will be turned on, intermittently, each time the patient looks down at the floor near their feet. Will be tested off-medication (after holding morning dopaminergic medications).
The augmented-reality visual cue will be turned on, intermittently, by an examiner, whenever they feel the patient is having a freezing episode or at risk of having a freezing episode. Will be tested off-medication (after holding morning dopaminergic medications).
Time frame: For each arm, during the single-day research visit only.
Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of gait freezing, derived from video recordings of gait performance, and body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of dysfunction, derived from kinematic recordings from body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of gait dysfunction, derived from kinematic recordings from body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of gait dysfunction, derived from augmented-reality headset and other body-worn wireless sensors
Time frame: For each arm, during the single-day research visit only.
Marker of gait freezing, derived from kinematic recordings from body-worn wireless sensors.
Time frame: For each arm, during the single-day research visit only.
Marker of gait freezing, derived from video recordings of gait performance, and body-worn wireless sensors.
The Cleveland Clinic
Other
Acronym: ELIMINATE-FOG
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05478187
Basal Ganglia Diseases, Brain Diseases
Ciserano, Bergamo, Italy
View Trial DetailsNCT01491932
Anti-Dyskinesia Agents, Basal Ganglia Diseases
Englewood, Colorado, United States
View Trial DetailsNCT01491529
Anti-Dyskinesia Agents, Basal Ganglia Diseases
Sunnyvale, California, United States
View Trial DetailsNCT01385592
Basal Ganglia Diseases, Brain Diseases
Sunnyvale, California, United States
View Trial Details